Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
staphylococcus aureus bacterial lysate
- Development stage
- Unknown
- Lead developer
- Laboratorio Farmaceutico SIT
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Topical
01
Overview
Staphylococcus aureus bacterial lysate is an immunostimulating agent composed of the lysed components of *Staphylococcus aureus* cells. Developed by Laboratorio Farmaceutico S.I.T. (Specialita' Igienico Terapeutiche), it is primarily indicated for the prevention and treatment of recurrent lower respiratory tract infections and other chronic staphylococcal infections, such as furunculosis and skin infections. The lysate acts by presenting bacterial antigens to the mucosal immune system, particularly through the activation of pattern recognition receptors like Toll-like receptors (specifically TLR2). This stimulation triggers both innate and adaptive immune pathways, enhancing the activity of macrophages and natural killer cells, and increasing the production of secretory IgA, thereby strengthening the body's defense against subsequent staphylococcal challenges.
- Brand names
- Stafal
- Other names
- Staphylococcal bacterial lysateStaphylococcal bacteriophage lysateLisato di Staphylococcus aureus
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on staphylococcus aureus bacterial lysate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on staphylococcus aureus bacterial lysate.